This wiki has undergone a migration to Confluence found Here
<meta name="googlebot" content="noindex">

Difference between revisions of "CG WG Call Notes leading to 2014 January WGM"

From HL7Wiki
Jump to navigation Jump to search
Line 5: Line 5:
  
 
==Attendees==
 
==Attendees==
* Amnon Shabo,  
+
* Amnon Shabo, Gil, Rubby, Grant, Scott
  
 
==Draft Minutes==
 
==Draft Minutes==

Revision as of 15:05, 22 October 2013

October 22, 2013 -- Weekly call

Proposed Agenda

  • Update on the Global Alliance by Gil

Attendees

  • Amnon Shabo, Gil, Rubby, Grant, Scott

Draft Minutes

October 15, 2013 -- Weekly call

Proposed Agenda

  • Discuss the CG DIM

Attendees

  • Amnon Shabo, Siew Lam, Grant Wood, Gil Alterovitz, Mollie, Phil Pochon, Yan Heras


Draft Minutes

  • Amnon went through a slide deck, each containing a model underlying one of the specs developed by the HL7 Clinical Genomics group, and then presented a sketch of thought on where we could go with the DIM

October 8, 2013 -- Weekly call

Proposed Agenda

  • Need to submit the Cambridge WGM Meeting Minutes by the end of this week
  • Change of WGM schedule
    • From Wednesday & Thursday to Tuesday & Wednesday
    • Do we need all session in both days?
      • Accommodates joints with AP and OO with solo meetings before the joints
      • So far we had a day and a half
      • We could run from Tuesday Q2 to Wednesday Q3

Attendees

  • Amnon Shabo, Siew Lam, Grant Wood, Larry Babb, Gil Alterovitz, Jenny, Ruby Russell, Mollie

Draft Minutes

  • Grant will start the Cambridge WGM minutes by inserting the attendees in each session; Amnon will add to it minutes as he can recall and send out to the mailing list so that people can add to it
  • Discussed the revisions to the CG DIM PSS and hearing no objections decided to resubmit to DESD
  • Discussed initial modeling considerations of the DIM
  • Amnon brought up the GTR, v2, v3 and FHIR models and made comments on the current differences
  • Is research use case part of the DIM?
  • Mollie said it should be clinically oriented with transnational capabilities at the most
  • Amnon said it's Universal in the sense that we start from common denominator and then allow each environment to constrain it as need; e.g., for clinical it should be highly constrained